For Physicians. By Physicians.™
For Physicians. By Physicians.™
This study by Zalel et al. (Prenatal Diagnosis, 2017) analyzed whether there was benefit to the use of detailed early fetal anatomy scans before karyotyping in patients with an increased nuchal translucency (NT).
Prospective Cohort Study
43 fetuses with NT >99th centile were surveyed. Before karyotyping, detailed fetal anatomy scans were performed. Sonographic findings were then analyzed to see if they could be used to predict fetal aneuploidy. The mean NT was 4.5mm at a gestational age of ~12 weeks. In 30 of the fetuses (69.8%) the scan uncovered significant anomalies. 24 underwent karyotyping and in 14 chromosomal abnormalities were found. Of the 13 fetuses whose scans were negative, one had aneuploidy. These results yield a PPV of 58.3% for the use of detailed scans in diagnosing aneuploidy after detection of increased NT and that ultrasound was an independent risk factor for aneuploidy, apart from NT.
The added value of detailed early anomaly scan in fetuses with increased nuchal translucency
Please log in to ObGFirst to access this page
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
